University of Patras
Μελέτη της ποιότητας ζωής και εφαρμογή θεραπευτικών μεθόδων σε ασθενείς που πάσχουν απο β-θαλασσαιμία στη Δυτική Ελλάδα
Abstract
dc:descriptionThis study mainly aimed at examining the quality of life of patients with homozygous beta-thalassemia in Western Greece, according to the iron chelation therapy (ICT) regimen they were receiving. Furthermore, among others, the study aimed at recording the sleep quality and quantity, and the patients’ satisfaction with their ICT. Study design and methodology: Overall, 131 patients with homozygous transfusion-dependent β-thalassemia attending the Thalassemia Units of the University Hospital of Patras (N=81), the Children Hospital “Karamandaneion” of Patras (N=29) and the General Hospital of Agrinio (N=21) between December 2018 and October 2019, participated in the study. All patients provided written informed consent for their participation in the study. Patients were categorized in two groups depending on whether they were receiving deferoxamine alone or in combination with an oral iron chelator (Group 1: n=80), or only an orally administered iron chelator (Group 2: n=51). All patients completed a questionnaire containing among others the 36-item Short Form (SF-36) health survey, the MOS-Sleep Scale, and the Satisfaction with Iron Chelation Therapy (SICT) questionnaire, assessing patient satisfaction from their therapy. Results: Of the 131 patients 74 were female and 57 male. The median age of the patients at enrollment was 41.0 years. Patients of Group 1 had been diagnosed and had initiated ICT at a younger age (median: 0.9 and 6.0 years, respectively), than those of Group 2 (median: 2.0 and 10.0 years, respectively). However, the two groups did not significantly differ in terms of duration of ICT until their enrollment in the study, age at the time of completing the questionnaires, gender, marital status, and employment status. At enrollment, 85.5% of patients of the overall population, 86.2% of those in Group 1 and 84.4% of those in Group 2, were suffering from at least one complication related to β-thalassemia and its treatment. The median SF-36 physical component summary (PCS) and mental component summary (MCS) scores were 76.3 and 75.7 among Group 1 patients and 76.9 and 74.5 among Group 2 patients, not differing between the two groups. In multivariable linear regression analysis, patients younger than 40 years were estimated to have a 16.1-point higher PCS (p=0.003) and a 13.2-point higher MCS (p=0.005) score, than those who were 40 years or older. In addition, patients, whose ICT included deferasirox were estimated to have an 11.4-point higher MCS score, than patients not receiving deferasirox (borderline non-significance; p=0.051), and higher SF-36 Bodily Pain domain score (mean score: 81.3 versus 71.6; p=0.050). In their majority, Group 1 (84.6%) and Group 2 (92.9%) patients reported preferring the oral route of ICT administration. Moreover, Group 1 versus Group 2 patients reported greater perceived effectiveness of their ICT (median scores: 4.3 versus 4.2; p=0.039). Nonetheless, patients receiving ICT containing versus not containing deferasirox reported higher acceptance (median scores: 4.0 versus 3.6; p=0.038) and greater satisfaction with the burden of their ICT (median scores: 4.4 versus 3.9; p=0.033). Finally, Group 1 patients reported higher sleep adequacy (p=0.037) and better overall sleep quality and quantity (p=0.022) than Group 2 patients. Conclusions: Patients with transfusion-dependent β-thalassemia in their majority prefer the oral route of ICT administration, are more accepting of and more satisfied from the burden of deferasirox-containing ICT, although in our sample, patients receiving parenteral ICT reported better sleep quality and quantity and higher satisfaction from the effectiveness of treatment. Therefore, it seems important to individualize the ICT based on the individual’s needs and preferences in order to maximize the clinical benefit.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Goulas, Vasileios
- Γούλας, Βασίλειος
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/48796